### Indication
- Osteosarcoma of bone and articular cartilage of unspecified sites

### INN
- Etoposide

### Medicine type
- Chemical agent

### List type
- Complementary (EML)
  - (EMLc)

### Formulations
- **Parenteral > General injections > IV:** 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
- **Oral > Solid:** 100 mg capsule; 50 mg capsule

### EML status history
- First added in 2021 (TRS 1035)
- Changed in 2023 (TRS 1049)

### Sex
- All

### Age
- Also recommended for children

### Therapeutic alternatives
- The recommendation is for this specific medicine

### Patent information
- Patents have expired in most jurisdictions
  - Read more about patents.

### Summary of evidence and Expert Committee recommendations
Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional dose form of etoposide (Powder for injection: 100 mg (as phosphate) in vial) to the EML and EMLc.